Table 3 Antibiotics susceptibilities of ESBL positive enterobacteriaceae isolates
Antibiotics | Frequency (%) | ||
|---|---|---|---|
Sensitive | Intermediate | Resistant | |
Ampicillin (n = 108) | 0 (0.0) | 0 (0.0) | 108 (100.0) |
Amoxicillin (n = 100) | 0 (0.0) | 0 (0.0) | 14 (100.0) |
Piperacillin–tazobactam (n = 61) | 24 (39.3) | 19 (31.1) | 18 (29.5) |
Amoxicillin-clavulanate (n = 79) | 1 (1.3) | 19 (24.1) | 59 (74.7) |
Ampicillin-sulbactam (n = 21) | 0 (0.0) | 2 (9.5) | 19 (90.5) |
Cefuroxime (n = 109) | 0 (0.0) | 0 (0.0) | 109 (100.0) |
Ceftazidime (n = 89) | 0 (0.0) | 3 (3.4) | 86 (96.6) |
Ceftriaxone (n = 56) | 0 (0.0) | 0 (0.0) | 56 (100.0) |
Cefotaxime (n = 106) | 0 (0.0) | 0 (0.0) | 106 (100.0) |
Cefepime (n = 90) | 0 (0.0) | 4 (4.4) | 86 (95.6) |
Gentamicin (n = 69) | 18 (26.1) | 2 (2.9) | 49 (71.0) |
Imipenem (n = 107) | 106 (99.1) | 0 (0.0) | 1 (0.9) |
Meropenem (n = 107) | 106 (99.1) | 1 (0.9) | 0 (0.0) |
Ertapenem (n = 104) | 103 (99.0) | 0 (0.0) | 1 (1.0) |
Ciprofloxacin (n = 79) | 7 (8.9) | 19 (24.1) | 53 (67.1) |
Cotrimoxazole (n = 90) | 14 (15.6) | 0 (0.0) | 76 (84.4) |
Nitrofurantoin (n = 9) | 0 (0.0) | 1 (11.1) | 8 (88.9) |